8-KMaterial AgreementsFinancial EventsSecurities & Listing+1

AMGEN INC 8-K Report, Material Agreement (Feb 21, 2006)

Filed February 21, 2006For Securities:AMGN

Summary

Amgen Inc. filed an 8-K on February 20, 2006, to report on a significant financing transaction. The company successfully issued $5 billion in aggregate principal amount of Convertible Senior Notes, split between $2.5 billion of 0.125% Notes due 2011 and $2.5 billion of 0.375% Notes due 2013. These notes were sold in a private placement to qualified institutional buyers, generating approximately $4.9 billion in net proceeds after fees. In conjunction with the note offering, Amgen also engaged in complex financial transactions involving convertible note hedge agreements and warrants. These arrangements were designed to offset potential dilution from the conversion of the notes and significantly impact the effective conversion price of the notes. Furthermore, the company announced an accelerated share repurchase program to buy back approximately 14.19 million shares of its common stock. This 8-K provides crucial details about the terms of the debt issuance, the associated derivative transactions, and the share buyback, all of which are material for understanding Amgen's capital structure and shareholder value strategies at the time.

Key Highlights

  • 1Amgen issued $5 billion in Convertible Senior Notes ($2.5B 0.125% due 2011 and $2.5B 0.375% due 2013) via a private placement.
  • 2The offering generated net proceeds of approximately $4.9 billion after discounts and expenses.
  • 3The notes have specific conversion triggers, including stock price thresholds (over 130% of conversion price for 20+ days in a quarter) and change of control events.
  • 4Amgen entered into convertible note hedge transactions (Purchased Call Options) costing approximately $1.5 billion to mitigate dilution.
  • 5The company simultaneously sold warrants (Sold Warrants) for approximately $775 million, with a strike price of $107.90 per share.
  • 6These hedge and warrant transactions effectively increase the conversion price of the notes to $107.90, representing a 50% premium over the February 14, 2006, stock price.
  • 7Amgen initiated an accelerated share repurchase program to buy back approximately 14.19 million shares of common stock at an initial price of $81.00 per share.

Frequently Asked Questions

The primary purpose of this 8-K filing was to disclose Amgen's entry into material definitive agreements related to the issuance of $5 billion in Convertible Senior Notes, the associated derivative transactions (convertible note hedges and warrants), and an accelerated share repurchase program. These events significantly alter the company's capital structure and shareholder equity.

Amgen raised approximately $4.9 billion in net proceeds from the issuance of $2.5 billion aggregate principal amount of 0.125% Convertible Senior Notes due 2011 and $2.5 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2013. The notes have specific conversion conditions and maturity dates.

The convertible note hedge transactions (purchased call options) were entered into to offset potential dilution if the notes are converted. The warrants sold generated proceeds but will require Amgen to issue stock or cash to the warrant holders if the stock price exceeds the warrant strike price. Together, these complex derivative transactions effectively increase the conversion price of the notes to $107.90 per share, thus protecting Amgen from significant dilution and influencing the cost of capital.

Amgen entered into an agreement to repurchase approximately 14.19 million shares of its common stock. This program allows the company to immediately retire shares, reducing outstanding share count, which can be accretive to earnings per share and signals management's confidence in the company's stock valuation.